LYS228 + Standard of care therapy

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intra-abdominal Infections

Conditions

Intra-abdominal Infections

Trial Timeline

May 15, 2018 → Sep 24, 2018

NCT ID

NCT03354754

About LYS228 + Standard of care therapy

LYS228 + Standard of care therapy is a phase 2 stage product being developed by Novartis for Intra-abdominal Infections. The current trial status is terminated. This product is registered under clinical trial identifier NCT03354754. Target conditions include Intra-abdominal Infections.

What happened to similar drugs?

3 of 16 similar drugs in Intra-abdominal Infections were approved

Approved (3) Terminated (0) Active (13)

✅MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazoleMerckApproved

✅Tigecycline + Imipenem/cilastatinPfizerApproved

✅Sevoflurane + propofol + remifentanilBaxterApproved

🔄Ceftolozane/Tazobactam + Metronidazole + Meropenem + PlaceboMerckPhase 3

🔄MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mgMerckPhase 3

🔄CXA-201 and metronidazole + MeropenemMerckPhase 3

🔄Imipenem+Cilastatin/RelebactamMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03377426	Phase 2	Withdrawn	Oct 19, 2018	Oct 28, 2019	Complicated Urinary Tract Infections
NCT03354754	Phase 2	Terminated	May 15, 2018	Sep 24, 2018	Intra-abdominal Infections

Competing Products

20 competing products in Intra-abdominal Infections

See all competitors

Product	Company	Stage	Hype Score
Relebactam 250 mg + Relebactam 125 mg + Imipenem/cilastatin + Matching placebo to relebactam	Merck	Phase 2	35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	40
MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) + metronidazole 500 mg	Merck	Phase 3	40
CXA-201 and metronidazole + Meropenem	Merck	Phase 3	40
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	40
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	35
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	35
Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks + MK0826, /Duration of Treatment : 8 Weeks + Comparator: metronidazole / Duration of Treatment: 8 Weeks	Merck	Phase 3	40
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	43
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	40
Ceftazidime-avibactam + metronidazole + Meropenem	Pfizer	Phase 3	40
Tigecycline + Imipenem/cilastatin	Pfizer	Approved	43
ceftazidime/NXL104 + metronidazole + meropenem	Pfizer	Phase 2	35
ATM-AVI + Metronidazole	Pfizer	Phase 2	35
Tigecycline (Tygacil)	Pfizer	Pre-clinical	26
Ceftazidime -avibactam + Meropenem + Metronidazole	Pfizer	Phase 2	35
PF-06947386 + Metronidazole	Pfizer	Phase 3	40
Tigecycline	Pfizer	Pre-clinical	26
CAZ-AVI + Metronidazole + Meropenem	Pfizer	Phase 3	40
ATM-AVI + MTZ + MER + COL	Pfizer	Phase 3	40